CRISPR QC

San Diego, United States Founded: 2021 • Age: 5 yrs
Real-time CRISPR gene editing analysis and optimization are provided.

About CRISPR QC

CRISPR QC is a company based in San Diego (United States) founded in 2021 by Ross Bundy.. CRISPR QC has raised $12.49 million across 4 funding rounds from investors including Xcellerant Ventures, Serra Ventures and EvoNexus. CRISPR QC offers products and services including CRISPR Analytics Platform™, RNP Formation Insight, DNA Target Binding Insight, and CLEAVE Insight. CRISPR QC operates in a competitive market with competitors including Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others.

  • Headquarter San Diego, United States
  • Founders Ross Bundy
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Crispr Qc™, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $12.49 M (USD)

    in 4 rounds

  • Latest Funding Round
    $10 M (USD), Series A

    Jan 02, 2024

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of CRISPR QC

CRISPR QC offers a comprehensive portfolio of products and services, including CRISPR Analytics Platform™, RNP Formation Insight, DNA Target Binding Insight, and CLEAVE Insight. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Measures real-time kinetics for CRISPR gene editing optimization.

Analyzes nucleic acid-protein interactions for efficient gRNA screening.

Quantifies RNP binding to target DNA in real-time.

Detects CRISPR-Cas cleavage activity for improved gene editing.

People of CRISPR QC
Headcount 10-50
Employee Profiles 4
Board Members and Advisors 3
Employee Profiles
People
Ross Bundy
President & Co-Founder
People
Susan Pede
Vice President Operations
People
Jason Lehmann
Senior Product Marketing Manager
People
Tim Cloutier
Chief Commercial Officer

Unlock access to complete

Board Members and Advisors
people
Kiana Aran
Board Member & Co-Founder
people
Toby Richardson
Board Member
people
Paul Grint
Board Member

Unlock access to complete

Funding Insights of CRISPR QC

CRISPR QC has successfully raised a total of $12.49M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series A — $10.0M
  • First Round

    (21 Mar 2022)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2024 Amount Series A - CRISPR QC Valuation Xcellerant Ventures
Jan, 2023 Amount Seed - CRISPR QC Valuation Serra Ventures
Aug, 2022 Amount Seed - CRISPR QC Valuation EvoNexus
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in CRISPR QC

CRISPR QC has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Xcellerant Ventures, Serra Ventures and EvoNexus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Xcellerant Ventures is focused on funding healthcare innovation.
Founded Year Domain Location
Venture capital fund focused on Agtech and multiple sectors
Founded Year Domain Location
12-18 month incubation programs are provided for startups in California.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by CRISPR QC

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - CRISPR QC

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Crispr Qc Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of CRISPR QC

CRISPR QC operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of gene therapy using CRISPR base editing to treat diseases
domain founded_year HQ Location
Gene transplantation platform for humanizing pig cells is developed.
domain founded_year HQ Location
RNA-editing technologies are provided for precision medicine applications.
domain founded_year HQ Location
Next-generation gene editing tools are developed for drug enhancement.
domain founded_year HQ Location
Genetic therapies for diseases are developed using prime editing technology.
domain founded_year HQ Location
A CRISPR-based gene-editing platform is developed for therapeutic applications.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about CRISPR QC

When was CRISPR QC founded?

CRISPR QC was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is CRISPR QC located?

CRISPR QC is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Who is the current CEO of CRISPR QC?

Ross Bundy is the current CEO of CRISPR QC. They have also founded this company.

Is CRISPR QC a funded company?

CRISPR QC is a funded company, having raised a total of $12.49M across 4 funding rounds to date.

What does CRISPR QC do?

Founded in 2021 and based in San Diego, United States, CRISPR QC operates in the biotechnology sector. Real-time analysis platforms for CRISPR gene editing are developed, including measurements of RNP formation, DNA target binding, and cleavage activity. These services facilitate gRNA design optimization and workflow efficiency enhancements. Data-driven insights are supplied to identify issues early, thereby minimizing troubleshooting and supporting resource allocation in gene editing research.

Who are the top competitors of CRISPR QC?

CRISPR QC's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.

What products or services does CRISPR QC offer?

CRISPR QC offers CRISPR Analytics Platform™, RNP Formation Insight, DNA Target Binding Insight, and CLEAVE Insight.

Who are CRISPR QC's investors?

CRISPR QC has 3 investors. Key investors include Xcellerant Ventures, Serra Ventures, and EvoNexus.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available